1-3 of 3
Eleanor Lisbon
Close
Sort by
Journal Articles

Pharmacodynamic Results from Phase 1 Studies of GBT021601, a Next-Generation HbS Polymerization Inhibitor for Treatment of Sickle Cell Disease

Modupe Idowu, Thinh Nguyen, Derek Lewis, Thokozeni Lipato, Erin M. Buckley, Rowan Brothers, Mariam Akbar, Sydney Triplett, Kobina Dufu, Eleanor Lisbon
Journal: Blood
Blood (2022) 140 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2022-167997
Published: 2022
Journal Articles

GBT021601, a Next Generation HbS Polymerization Inhibitor: Results of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Adults Living with Sickle Cell Disease and Healthy Volunteers

R. Clark Clark Brown, Andrew Redfern, Eleanor Lisbon, Carla Washington, Irene Agodoa, Kim Smith-Whitley
Journal: Blood
Blood (2021) 138 (Supplement 1): 3099.
https://doi.org/10.1182/blood-2021-152924
Published: 2021
Journal Articles

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Lanetta Bronte-Hall, MD MPH, MSPH, Biree Andemariam, MD, Blyden Gershwin, MD, Sanne Lugthart, MD PhD, Timothy Mant, MB, FFPM, FRCP, Jo Howard, MBBChir, MRCP, FRCPath, Henry Fok, MBBS, PhD, Perla Eleftheriou, FRCPath, MRCP, Robert Ward Hagar, MD, James Mason, DO, Rahul Ballal, PhD, Joelle Lufkin, MPH, Eleanor Lisbon, MD MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
https://doi.org/10.1182/blood-2020-140540
Published: 2020